Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer
Autore:
Sweeney, CJ; Hermans, BP; Heilman, DK; Foster, RS; Donohue, JP; Einhorn, LH;
Indirizzi:
Indiana Univ, Med Ctr, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202USA Indiana Univ Indianapolis IN USA 46202 l Oncol, Indianapolis, IN 46202USA Indiana Univ, Med Ctr, Dept Urol, Indianapolis, IN 46202 USA Indiana UnivIndianapolis IN USA 46202 t Urol, Indianapolis, IN 46202 USA Indiana Univ, Med Ctr, Dept Med, Div Biostat, Indianapolis, IN 46202 USA Indiana Univ Indianapolis IN USA 46202 iostat, Indianapolis, IN 46202 USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 2, volume: 18, anno: 2000,
pagine: 358 - 362
SICI:
0732-183X(200001)18:2<358:RAOORL>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
GERM-CELL CANCER; TESTICULAR CANCER; CHEMOTHERAPY; SURVEILLANCE; FERTILITY; EJACULATION; TERATOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Einhorn, LH Indiana Univ, Med Ctr, Dept Med, Div Hematol Oncol, Indiana Canc Pavil,535Barnhill Dr,Room 473, Indianapolis, IN 46202 USA Indiana Univ Indiana Canc Pavil,535 Barnhill Dr,Room 473 Indianapolis IN USA 46202
Citazione:
C.J. Sweeney et al., "Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer", J CL ONCOL, 18(2), 2000, pp. 358-362

Abstract

Purpose: To determine the incidence of metastatic disease and usage of chemotherapy (adjuvant or metastatic) after primary retroperitoneal lymph nodedissection (RPLND) in patients with clinical stage (CS) I embryonal carcinoma (EC)-predominant testicular cancer. EC predominance was defined as the presence of EC at a level greater than that of any other histologic diagonsis. Patients and Methods: All CS I patients with non-seminomatous germ cell tumors who underwent RPLND at Indiana University from 1990 to 1995 were reviewed retrospectively,Results: Two-year follow-up was available for 292 of 320 patients, EC-predominant disease was found in 125 (42.8%) of 292. Eighty-five (68.0%) of 125patients with EC-predominant disease had pathologic stage (PS) I, and 18 (21.2%) of this group of 85 relapsed, A significantly lower PS I relapse rare of 3% was found for patients who had non-EC-predominant disease (P < .0001). PS II disease was more frequent in patients with EC predominance, as 40(32.0%) of 125 held retroperitoneal metastases, compared with 26 (15.6%) of 167 patients with a non-EC-predominant histologic diagnosis (P = .0024). Chemotherapy was administered to 48 (38.4%) of the 125 patients with CS I EC-predominant disease after RPLND. This included 25 CS I patients with PS II disease who received adjuvant chemotherapy in addition to 23 patients whosubsequently required chemotherapy for relapse after RPLND, Ten (66.6%) of15 PS II EC-predominant patients were cured by surgery alone. Currently, all 125 EC-predominant patients are disease-free. Conclusion: patients with CS I EC-predominant disease are at a relatively high risk for metastatic disease. (C) 2000 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 21:59:14